Company intelligence / Profile preview

Medeor Therapeutics

South San Francisco, California, United Statesmedeortx.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 3

Overview

Medeor completed a pivotal Phase 3 trial with its lead product candidate MDR‑101, a single-dose cellular therapy derived from a living kidney donor’s blood. The study exceeded its target success rate—patients achieved functional immune tolerance and were able to discontinue all immunosuppressive drugs without graft loss or acute rejection. Results are under peer review. Operations have been suspended pending acquisition to complete the BLA filing.[1][4]

Therapeutic areas: HematologyImmunologyNephrology
Modalities: Cellular immunotherapyHematopoietic stem cell therapy[7]
Industry: Biotech

Drug pipeline

4 assets

sizavaleucel

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Medeor Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medeor Therapeutics.

Explore the full profile